A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
Korean Journal of Hematology
;
: 73-75, 2010.
Artigo
em Inglês
| WPRIM
| ID: wpr-720282
ABSTRACT
Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been associated with reduced alpha2-plasmin inhibitor and platelet dysfunction. We report here the case of a 33-year-old female patient with CML who experienced subdural hematoma after an incremental increase in IM dosage due to a loss of complete molecular response. This case indicates that physicians should be alert to this atypical cause of headache in patients taking high-dose IM.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Plaquetas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Philadelphia
/
Incidência
/
Mesilatos
/
Mesilato de Imatinib
/
Cefaleia
Tipo de estudo:
Estudo de incidência
/
Estudo prognóstico
Limite:
Adulto
/
Feminino
/
Humanos
País/Região como assunto:
América do Norte
Idioma:
Inglês
Revista:
Korean Journal of Hematology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS